Funding round-up: SantéVet, LenioBio, GluBio Pharmaceutical, Synapse Medicine, Scenic Biotech

The Netherlands: Scenic Biotech, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders, has closed a Series A financing of €28m (US$30.6m). Funds will be used to accelerate Scenic’s transition into a development stage company, advancing its in-house pipeline and supporting the creation of…

You must be a HMI Subscriber to view this content.

Subscribe Now »